Dahia P L, Marsh D J, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115-6084, USA.
Cancer Res. 1997 Nov 1;57(21):4710-3.
The majority of familial medullary thyroid neoplasms are associated with germ-line mutations of the RET proto-oncogene, yet very little is known about the mechanisms involved in the pathogenesis of familial and sporadic nonmedullary thyroid tumors. A subset of thyroid tumors have loss of heterozygosity of chromosome 10q22-23, a region harboring the gene responsible for Cowden disease, an autosomal dominant hamartoma syndrome associated with thyroid and breast tumors. PTEN/MMAC1/TEP1 codes for a dual-specificity phosphatase and is likely a tumor suppressor gene. We sought to determine the PTEN status in a series of epithelial thyroid neoplasms. We studied 95 sporadic thyroid tumors, of which 39 were papillary thyroid carcinomas (PTCs), 12 were follicular carcinomas, 9 were anaplastic carcinomas, 5 were Hürthle cell carcinomas, 21 were nonfunctioning follicular adenomas, and 9 were Hürthle cell adenomas. Direct sequencing of PCR-amplified products was performed for all nine exons of PTEN. Two polymorphic markers, one located in intron 8 and another, a dinucleotide repeat marker, AFMa086wg9, located within intron 2, were analyzed in paired blood-tumor DNA samples to assess hemizygous deletions of PTEN. We found a somatic frameshift mutation in one PTC, which was expected to generate a premature stop codon 2 amino acids downstream. Twenty-six % of informative benign tumors (four follicular adenomas and three Hürthle cell adenomas) and only 3 of 49 (6.1%) informative malignant tumors (one PTC, one follicular carcinoma, and one anaplastic carcinoma) showed evidence of hemizygous deletion of PTEN (P = 0.046). We conclude that a subset of thyroid tumors have somatic deletions of the PTEN gene, predominantly the benign forms, and that small intragenic mutations of PTEN are infrequent in thyroid tumors. We speculate that other mechanisms of PTEN inactivation, rather than small intragenic mutations, might occur in the hemizygously deleted samples and act as the "Knudson second hit." Alternatively, other tumor suppressor genes mapping to chromosome 10q22-23 could be the actual targets for such deletions and thus represent the various hits in the pathway of multistep carcinogenesis.
大多数家族性甲状腺髓样肿瘤与RET原癌基因的种系突变相关,但对于家族性和散发性非髓样甲状腺肿瘤发病机制所涉及的机制却知之甚少。一部分甲状腺肿瘤存在10q22 - 23染色体杂合性缺失,该区域含有与考登病相关的基因,考登病是一种与甲状腺和乳腺肿瘤相关的常染色体显性错构瘤综合征。PTEN/MMAC1/TEP1编码一种双特异性磷酸酶,可能是一种肿瘤抑制基因。我们试图确定一系列甲状腺上皮性肿瘤中的PTEN状态。我们研究了95例散发性甲状腺肿瘤,其中39例为乳头状甲状腺癌(PTC),12例为滤泡状癌,9例为未分化癌,5例为许特莱细胞癌,21例为无功能滤泡性腺瘤,9例为许特莱细胞腺瘤。对PTEN的所有9个外显子进行了PCR扩增产物的直接测序。在配对的血液 - 肿瘤DNA样本中分析了两个多态性标记,一个位于内含子8,另一个是位于内含子2内的二核苷酸重复标记AFMa086wg9,以评估PTEN的半合子缺失。我们在一个PTC中发现了一个体细胞移码突变,预计该突变会在下游2个氨基酸处产生一个提前终止密码子。26%的信息丰富的良性肿瘤(4例滤泡性腺瘤和3例许特莱细胞腺瘤)以及49例信息丰富的恶性肿瘤中仅3例(6.1%)(1例PTC、1例滤泡状癌和1例未分化癌)显示有PTEN半合子缺失的证据(P = 0.046)。我们得出结论,一部分甲状腺肿瘤存在PTEN基因的体细胞缺失,主要是良性肿瘤,并且PTEN的小基因内突变在甲状腺肿瘤中不常见。我们推测,在半合子缺失的样本中可能发生PTEN失活的其他机制,而不是小基因内突变,并充当“克努森二次打击”。或者,定位于10q22 - 23染色体的其他肿瘤抑制基因可能是这种缺失的实际靶点,因此代表了多步骤致癌途径中的各种打击。